+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 12Years - 59Years
All Genders
Healthy Volunteers
ID07087912

Evaluating Safety and Immune Response of the Live Attenuated Butantan-Dengue Vaccine in People Aged 12 to 59 with Autoimmune Rheumatic Diseases and Healthy Volunteers

Led by University of Sao Paulo General Hospital · Updated on 2026-07-20

477

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety and immune response of the live attenuated tetravalent Butantan-Dengue vaccine Butantan-DV in people aged 12 to 59 years with autoimmune rheumatic diseases ARDs who are clinically stable and under low-grade or no immunosuppression, compared to healthy volunteers matched by age and sex. The study addresses important questions about whether the vaccine triggers adequate antibody responses, the frequency and intensity of common side effects, and how physical activity and nutrition might affect vaccine response in ARD patients. Participants will receive a single 0.5 mL dose of the Butantan-DV vaccine by subcutaneous injection on Day 1. Follow-up visits for safety and laboratory tests occur on Days 7, 14, and 42, with long-term monitoring extending to Day 400 to assess antibody persistence and late safety signals. A subgroup will undergo additional blood sampling to evaluate viremia up to Day 68 if detected, and about 20% of participants will have cellular immune response testing at baseline, Day 42, and Day 400. Participants will provide blood samples before vaccination, at Day 42, and one year after to assess immune response. They will report symptoms and adverse events for 42 days using a diary, wear a device for 14 days to monitor physical activity, and complete dietary recalls to evaluate nutrition. Disease activity and safety will be closely monitored throughout, with assessments to distinguish vaccine effects from disease flares. The study duration for participants extends up to one year after vaccination.

CONDITIONS

Brief Title

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Research Team

C

Clovis A Silva, Full Professor

E

Eloisa SDO Bonfa, Full Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here